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Recent ﬁndings suggested that the SUMO-interacting motifs (SIMs) present in the human TRIM5a
(TRIM5ahu) protein play an important role in the ability of TRIM5ahu to restrict N-MLV. Here we
explored the role of SIMs in the ability of rhesus TRIM5a (TRIM5arh) to restrict HIV-1, and found that
TRIM5arh SIM mutants IL376KK (SIM1mut) and VI405KK (SIM2mut) completely lost their ability to
block HIV-1 infection. Interestingly, these mutants also lost the recently described property of
TRIM5arh to shuttle into the nucleus. Analysis of these variants revealed that they are unable to
interact with the HIV-1 core, which might explain the reason that these variants are not active against
HIV-1. Furthermore, NMR titration experiments to assay the binding between the PRYSPRY domain of
TRIM5arh and the small ubiquitin-like modiﬁer 1(SUMO-1) revealed no interaction. In addition, we
examined the role of SUMOylation in restriction, and ﬁnd out that inhibition of SUMOylation by the
adenoviral protein Gam1 did not alter the retroviral restriction ability of TRIM5a. Overall, our results do
not support a role for SIMs or SUMOylation in the antiviral properties of TRIM5a.
& 2012 Elsevier Inc. All rights reserved.Introduction
Several newly discovered proteins endogenously expressed in
primates show the ability to dominantly block retroviral infection
and cross-species transmission by interfering with the early phase of
viral replication (Kirmaier et al., 2010; Sayah et al., 2004; Stremlau
et al., 2004). Of particular interest are members of the tripartite
motif (TRIM) family of proteins (Reymond et al., 2001). The splicing
variant alpha of TRIM5 from rhesus macaque (TRIM5arh) is a
53 kDa cytosolic protein that potently restricts HIV-1(Keckesova
et al., 2004; Song et al., 2005a). TRIM5arh blocks HIV-1 and certain
other retroviruses soon after viral entry, but prior to reverse
transcription (Keckesova et al., 2004; Stremlau et al., 2004). The
retroviral capsid protein (CA) is the viral determinant for suscept-
ibility for restriction by TRIM5a (Owens et al., 2003). Studies on the
fate of the HIV-1 capsid in the cytosol of infected cells have
correlated restriction with a decrease in the amount of cytosolic
particulate capsid (Diaz-Griffero et al., 2007a, 2008; Perron et al.,
2007; Roa et al., 2012; Stremlau et al., 2006), suggesting that
TRIM5arh acts by inducing premature uncoating in target cells.ll rights reserved.
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du (F. Diaz-Griffero).TRIM5arh is composed of four distinct domains: RING, B-box 2,
coiled-coil and PRYSPRY (Reymond et al., 2001). The RING domain
of TRIM5arh is an E3 ubiquitin ligase (Diaz-Griffero et al., 2006a;
Kar et al., 2008; Kim et al., 2011; Langelier et al., 2008; Lienlaf
et al., 2011; Maegawa et al., 2010; Yamauchi et al., 2008). The E3-
ligase activity of TRIM5arh correlates with the ability of TRIM5arh
to block HIV-1 (Lienlaf et al., 2011; Roa et al., 2012). The B-box
2 domain of TRIM5arh and other TRIM proteins, such as TRIM63,
self-associates into dimeric complexes that are important for
TRIM5a higher-order self-association and capsid binding avidity;
these B-box 2 domain functions are essential for full and potent
restriction of HIV-1 (Diaz-Griffero et al., 2007b, 2009; Ganser-
Pornillos et al., 2011Javanbakht et al., 2005; Mrosek et al., 2008;
Perez-Caballero et al., 2005). The coiled-coil domain enables
TRIM5arh dimerization (Kar et al., 2008; Langelier et al., 2008),
which is critical for interaction of the PRYSPRY domain with the
HIV-1 capsid (Diaz-Griffero et al., 2006b; Sebastian and Luban,
2005; Stremlau et al., 2006). The PRYSPRY domain is the capsid
recognition module that dictates the speciﬁcity of restriction
(Biris et al., 2012; Nakayama et al., 2005; Sawyer et al., 2005;
Song et al., 2005b; Stremlau et al., 2005; Yap et al., 2005).
Recent discoveries have demonstrated that TRIM5arh has the
ability to shuttle into the nucleus and then exported back into the
cytoplasm by a CRM-1 dependent mechanism (Diaz-Griffero
et al., 2011). This work demonstrated that the use of the CRM-1
Fig. 1. Contribution of TRIM5arh SUMO-conjugation and SUMO-interacting
motifs(SIM) to restriction of HIV-1. Dog Cf2Th cells were transduced with the
LPCX vector expressing HA-tagged wild-type and mutant TRIM5arh proteins. The
A. Brandariz-Nun˜ez et al. / Virology 435 (2013) 463–471464inhibitor, Leptomycin B (LMB) (Fornerod et al., 1997; Kudo et al.,
1998; Kuersten et al., 2001; Mohr et al., 2009; Watanabe et al.,
1999; Wolff et al., 1997), induced the accumulation of TRIM5arh
in the nuclear compartment; however, the ability of TRIM5arh
to restrict HIV-1 infection was not altered by the use of LMB
(Diaz-Griffero et al., 2011). Because the use of LMB leads to
accumulation of TRIM5arh in the nucleus while de novo synthesis
of TRIM5arh occurs in the cytoplasm, it is difﬁcult to know
whether the shuttling of TRIM5arh through the nucleus is impor-
tant for HIV-1 restriction. Therefore, the contribution of the
nuclear shuttling properties of TRIM5arh to HIV-1 restriction is
not understood.
The addition of small ubiquitin-related modiﬁers (SUMO) to
cellular proteins, a process known as SUMOylation (Johnson,
2004), is linked to the targeting of cytosolic proteins to the
nuclear compartment (Wang et al., 2012). Recent work suggested
that SUMO-interacting motifs (SIMs) in the human TRIM5a
(TRIM5ahu) protein are involved in the ability of TRIM5ahu to
restrict N-tropic murine leukemia virus (N-MLV) (Arriagada et al.,
2011). This work showed that mutation of the SIMs of TRIM5ahu
inactivates its restriction capability (Arriagada et al., 2011). These
studies, however, did not test whether TRIM5ahu bearing mutated
SIMs lost its ability to shuttle into and out of the nucleus.
To understand the role of TRIM5arh nuclear-shuttling and
SUMOylation in HIV-1 restriction by TRIM5arh, we performed
the following studies: (1) contribution of SUMO-conjugating
motifs (SCM) and SIM to the ability of TRIM5arh to restrict HIV-
1 was examined by independent mutagenesis of these motifs, (2)
ability of TRIM5arh SCM and SIM variants to shuttle into the
nucleus by the use of LMB, (3) ability of TRIM5arh variants to bind
in vitro assembled HIV-1 capsid–nucleocapsid complexes and
oligomerization, (4) ability of the SUMOylation inhibitor Gam1
to affect N-MLV restriction by cells that endogenously express
TRIM5ahu, and (5) ability of the puriﬁed PRYSPRY domain of
TRIM5arh to interact with SUMO-1.TRIM5arh SUMO-conjugation motif (SCM1) and the three SUMO-interacting
motifs (SIM1, SIM2 and SIM3) variants are shown with their respective amino
acid position (A). Stable cell lines were selected with 5 mg/ml puromycin, and the
expression levels of mutant and wild-type TRIM5arh proteins were assayed by
Western blotting using anti-HA and anti-GAPDH antibodies (B). Stable cell lines
were challenged with different amounts of HIV-1-GFP (C). The percentage of GFP-
positive cells was measured 48 h later by FACS. The results of three independent
experiments were similar; the results of a single experiment are shown.Results
Role of SUMO-interacting and SUMO-conjugation motifs in HIV-1
restriction by TRIM5arh
Previous work has reported that N-MLV restriction by
TRIM5ahu requires the presence of intact SUMO-interacting
motifs in the PRYSPRY domain of TRIM5ahu (Arriagada et al.,
2011). To test the role of SUMO-interacting motifs (SIMs) and
SUMO-conjugation motifs (SCMs) in the ability of TRIM5arh to
restrict HIV-1, we independently mutated the K10R (SCM1mut),
the IL376KK (SIM1mut), the VI405KK (SIM2mut) and the IV430KK
(SIM3mut) (Fig. 1A). The TRIM5arh variants were stably expressed
in dog Cf2Th cells (Fig. 1B), and the ability of TRIM5arh variants to
restrict HIV-1 was tested (Fig. 1C). In agreement with observa-
tions studying TRIM5ahu SCMmut and SIMmut motifs, we found
that TRIM5arh SIM1mut and SIM2mut did not restrict HIV-1
suggesting the involvement of SIMs in restriction (Fig. 1C). By
contrast, TRIM5arh SCM1mut and SIM3mut blocked HIV-1 infec-
tion as potent as wild type. These results suggested that SIMs are
important for the ability of TRIM5arh to block HIV-1 infection.
Role of SIM1 and SIM2 in the ability of TRIM5arh to shuttle into and
out of the nucleus
We have previously described the ability of TRIM5arh to
shuttle into and out of the nucleus (Diaz-Griffero et al., 2011).
Because of SUMO’s involvement in the nuclear import of cellular
proteins (Wang et al., 2012), we tested the role of SIMs in theability of TRIM5arh to shuttle into and out of the nucleus. For this
purpose, we studied the localization of TRIM5arh variants by
immunoﬂuorescence microscopy in the presence of leptomycin B
(LMB), which is a speciﬁc inhibitor of nuclear export (Fornerod
et al., 1997; Kudo et al., 1998; Kuersten et al., 2001; Mohr et al.,
2009; Watanabe et al., 1999; Wolff et al., 1997). As shown in
Fig. 2, TRIM5arh SIM1mut and SIM2mut were not retained in the
nuclear compartment in the presence of LMB for 5 or 12 h when
compared to wild type TRIM5arh (Supplementary Table 1). These
experiments suggested that TRIM5arh-SIM1mut and TRIM5arh-
SIM2mut have lost their ability to trafﬁc into the nucleus. By
contrast, TRIM5arh SCM1mut and SIM3mut were retained in the
nucleus similar to wild type TRIM5arh (Fig. 2 and Supplementary
Table 1). These experiments suggested that SIM1 and SIM2 are
involved in the translocation of TRIM5arh into the nucleus.
Binding of TRIM5arh variants to in vitro assembled HIV-1 capsid–
nucleocapsid (CA–NC) complexes
The PRYSPRY domain of TRIM5arh mediates the interaction
between TRIM5arh and the HIV-1 core (Ohkura et al., 2006; Song
et al., 2005c; Stremlau et al., 2006). Because TRIM5arh SIM1mut
and SIM2mut are located in the PRYSPRY domain, which could
Fig. 2. Intracellular distribution of TRIM5arh SIM mutant proteins in the presence of leptomycin B. Human HeLa cells expressing the indicated TRIM5arh variants were
treated with 20 ng/ml of leptomycin B (LMB) or DMSO for either 5 or 12 h. Treated cells were ﬁxed and immunostained using anti-HA antibodies (green). Cellular nuclei
were stained by using DAPI (blue). Representative ﬁgures are shown. The results of three independent experiments were similar (Supplementary Table 1); the result of a
single experiment is shown.
Fig. 3. Binding of TRIM5arh SIM mutant proteins to in vitro assembled HIV-1
capsid–nucleocapsid (CA–NC) complexes. Human 293T cells were transfected
with plasmids expressing the indicated wild-type and mutant HA-tagged
TRIM5arh proteins. Forty-eight hours after transfection, cells were lysed. The
lysates were incubated at room temperature for 1 h with in vitro assembled HIV-1
CA–NC complexes. The mixtures were applied to a 70% sucrose cushion and
centrifuged. INPUT represents the lysates analyzed by Western blotting before
being applied to the 70% cushion. The input mixtures were Western blotted using
anti-HA antibodies. Similarly, the pellets from the 70% cushion (BOUND) were
analyzed by Western blotting using anti-HA and anti-p24 antibodies. The results
of three independent experiments were similar; the result of a single experiment
is shown.
A. Brandariz-Nun˜ez et al. / Virology 435 (2013) 463–471 465affect the ability of TRIM5arh to bind the HIV-1 core (Stremlau
et al., 2006); we examined the ability of the different TRIM5arh
variants to bind in vitro assembled HIV-1 CA–NC complexes
(Fig. 3), as previously described (Lienlaf et al., 2011; Roa et al.,
2012; Stremlau et al., 2006). Interestingly, TRIM5arh SIM1mut
and SIM2mut lost their ability to bind the HIV-1 core when
compared to wild type TRIM5arh. These results explain the
inability of TRIM5arh SIM1mut and SIM2mut variants to block
HIV-1 infection (Fig. 1C). By contrast, TRIM5arh SCM1mut andTRIM5arh SIM3mut bound in vitro assembled HIV-1 CA–NC
complexes similar to wild type TRIM5arh. These results suggested
that the inability of TRIM5arh SIM1mut and SIM2mut to block
HIV-1 infection is due to their failure to bind in vitro assembled
HIV-1 CA–NC complexes.
Oligomerization of TRIM5arh variants
Next we examined the ability of TRIM5arh variants to oligo-
merize by cross-linking using glycolbis-succinimidylsuccinate
(EGS), as previously described (Diaz-Griffero et al., 2007b; Kar
et al., 2008; Langelier et al., 2008). As shown in Fig. 4, cross-
linking experiments suggested that all TRIM5arh variants studied
here efﬁciently form oligomers. This observation is consistent
with previous results demonstrating that the coiled-coil is the
only domain required for oligomerization (Javanbakht et al.,
2006).
Role of SUMOylation in the ability of TRIM5ahu to restrict N-MLV
Our results suggested that TRIM5arh SIM1mut and SIM2mut
do not restrict HIV-1 because of their inability to bind the HIV-1
core; however, these results do not exclude the possibility that
SUMOylation is a necessary process for the capacity of TRIM5a to
restrict retroviruses, as previously suggested (Arriagada et al.,
2011). To understand the role of SUMOylation in restriction, we
took advantage of the avian adenoviral protein Gam1, which
inhibits protein SUMOylation in human cells by degradation of
SUMO E1 and E2 enzymes (Boggio et al., 2004, 2007; Colombo
et al., 2002). To understand the role of SUMOylation in N-MLV
restriction by cells endogenously expressing TRIM5ahu, we chal-
lenged the ﬁbrosarcoma human HT-1080 cell line with different
amounts of N-tropic murine leukemia virus bearing the green
ﬂuorescent protein as a reporter (N-MLV–GFP) in the presence of
Gam1 (Fig. 5A and B). Expression of the SUMOylation inhibitor
Fig. 4. Oligomerization of TRIM5arh SIM mutant proteins. Lysates from 293T
cells expressing wild-type and mutant TRIM5arh proteins were cross-linked with
increasing concentrations of ethylene glycol-bis(succinimidyl succinate) (EGS),
and were subjected to Western blotting using anti-HA antibodies, as described in
Materials and methods. ‘‘m’’ and ‘‘d’’ stands for monomer and dimer, respectively.
Similar results were obtained in three independent experiments and a represen-
tative experiment is shown.
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N-MLV–-GFP infection (Fig. 5A and B). As control, we performed
similar infections in the presence of the mutant Gam1-L258A/
L265A, which is unable to inhibit the SUMOylation pathway
(Boggio et al., 2004; Chiocca et al., 1997; Colombo et al., 2002).
To rule out the possibility that inhibition of SUMOylation is
affecting N-MLV infection, we challenged HT-1080 cells with
B-tropic MLV bearing a GFP reporter (B-MLV–GFP) in the presence
of Gam1 (Fig. 5A and B). The expression of Gam1 in HT-1080 cells
did not affect the infection of B-MLV–GFP suggesting that Gam1
did not interfere with the process of infection (Fig. 5A). Because
inhibition of SUMOylation by expression of Gam1 destroys
nuclear bodies that contain promyelocytic leukemia (PML) pro-
tein (Colombo et al., 2002), we tested whether expression of
Gam1 in human HT-1080 cells displayed the same effect (Fig. 5C).
As expected, expression of Gam1 destroyed PML-containing
nuclear bodies in HT-1080 cells when compared to Gam1-
L258A/L265A (Fig. 5C and Supplementary Fig. 1). Overall these
results showed that inhibition of SUMOylation by expression of
Gam1 does not affect the ability of TRIM5ahu to restrict N-MLV
suggesting that TRIM5ahu does not require SUMOylation for
restriction of N-MLV.Inhibition of SUMOylation by Gam1 did not affect the ability of
TRIM5arh to trafﬁc into the nucleus
Because SUMOylation is important for nuclear import of
cellular proteins (Wang et al., 2012), we tested whether SUMOy-
lation is necessary for the ability of TRIM5arh to shuttle into the
nucleus (Diaz-Griffero et al., 2011). For this purpose, we examined
the subcellular localization of transiently transfected HT-1080
cells with HA-tagged TRIM5arh (TRIM5arh-HA) and Gam1 in the
presence of LMB (Fig. 6 and Supplementary Table 2). As pre-
viously shown (Diaz-Griffero et al., 2011), the treatment with
LMB accumulated TRIM5arh-HA proteins in the nuclear compart-
ment; however, expression of Gam1 did not diminish or alter the
accumulation of TRIM5arh-HA proteins in the nuclear compart-
ment. To show that TRIM5arh does not interfere with the
biological activity of Gam1, we demonstrated that Gam1
destroyed PML-nuclear bodies in the presence of TRIM5arh
(Supplementary Fig. 2). These results suggested that SUMOylation
is not involved in the ability of TRIM5arh to shuttle into the
nucleus.The PRYSPRY domain of TRIM5arh does not interact with SUMO-1
To test whether the protein SUMO-1 can interact with the
PRYSPRY domain of TRIM5arh (residues 292–497),we performed
NMR titrations of the 15N-labeled rhesus PRYSPRY domain with
the unlabeled SUMO-1 protein. NMR titrations are sensitive to
even very weak protein–protein interactions and can be used to
map the interaction surfaces of the PRYSPRY domain (Biris et al.,
2012). As shown in Fig. 7A, the addition of a ﬁve-fold excess of
SUMO-1 to the PRYSPRY domain, did not produce observable
shifts on the NMR signals in the 15N –HSQC spectrum. In some
cases protein–protein interactions can produce attenuation rather
than shifts of the peaks in the NMR spectra; however, Fig. 7B
showed that no signal attenuation was observed in NMR titra-
tions of the PRYSPRY domain with SUMO-1. By contrast, signal
attenuation is clearly visible in the titration of PRYSPRY with the
N-terminal domain of the HIV-1 capsid, a protein that interacts
with the PRYSPRY domain very weakly with a Kd 400 mM (Biris
et al., 2012). Thus, no interaction between the PRYSPRY domain of
TRIM5arh and SUMO-1 was detected even at SUMO-1 concentra-
tion of up to 1.5 mM.
Mapping of SIM residues on the PRYSPRY domain of TRIM5arh
We have recently solved the structure of the PRYSPRY domain
of TRIM5arh (Biris et al., 2012). SIM1, SIM2 and SIM3 motifs were
predicted based on the consensus amino acid sequence, but these
hydrophobic amino acid motifs have to be exposed on the protein
surface in order to mediate protein–protein interactions. Inspec-
tion of the TRIM5arh PRYSPRY structure revealed that out of the
three predicted SIM motifs, only SIM3 contains surface-exposed
residues, while SIM1 and SIM2 are buried in the hydrophobic core
of the PRYSPRY structure; therefore, SIM1 and SIM2 cannot
mediate protein–protein interactions (Fig. 8).Discussion
The recent discovery of the ability of TRIM5arh and TRIM5ahu
to shuttle into and out of the nucleus suggested the exiting
possibility that the nuclear shuttling ability of TRIM5a is playing
a role in restriction (Diaz-Griffero et al., 2011). Since SUMOylation
is important for the ability of some cellular proteins to shuttle
into the nucleus and recent ﬁndings suggested a role for SIM in
restriction (Arriagada et al., 2011), here we explored the role of
SCM, SIM and SUMOylation in the ability of TRIM5a to restrict
retroviral infection.
In agreement with previous observations (Arriagada et al.,
2011), we found that changes TRIM5arh SIM1mut and SIM2mut
lost their ability to restrict HIV-1. Interestingly, both TRIM5arh
variants also lost their ability to shuttle into the nucleus. How-
ever, these variants were unable to bind in vitro assembled HIV-1
CA–NC complexes, which suggest that these TRIM5arh variants
are unable to restrict HIV-1 because of their impaired binding to
the HIV-1 core. The most likely explanation is that TRIM5arh
SIM1mut and SIM2mut contain a misfolded PRYSPRY domain.
In agreement, analysis of SIM1 and SIM2 motifs in the structure of
the PRYSPRY domain revealed that these motifs are buried in the
hydrophobic core of the protein, and their mutation to charged
residues is likely to disrupt the structural integrity of the PRYSPRY
domain (Fig. 8). Taken together, we would like to suggest that
TRIM5arh SIM1mut and SIM2mut are proteins that contain a
misfolded PRYSPRY domain, and this is the reason that they are
unable to restrict retroviral infection.
Although our results do not support a role for SUMOylation in
the ability of TRIM5arh to restrict HIV-1, this work does not
Fig. 5. Role of SUMOylation in the ability of TRIM5ahu to restrict N-MLV. Human HT-1080 cells were transienly transfected with plasmids expressing Myc-tagged Gam1
or Gam1-L258A/L265A. After 24 h, cells were challenged with increasing amounts of N-MLV-GFP or B-MLV-GFP. Viruses expressing the reproter GFP were normilized in
dog Cf2Th cells. Forthy-eight hours post-transfection, infection was determined by counting the percentage of GFP-positive cells using FACS (A). The expression of Gam1
and Gam1-L258A/L265A were analyzed by Western blotting using anti-Myc and anti-GAPDH antibodies (B). The ability of Gam1 to destroy PML-containing nuclear bodies
was assayed by transiently transfecting HT-1080 cells with plasmids expressing Gam1 or Gam1-L258A/L265A tagged with a Myc epitope. After 24 h, cells were ﬁxed and
immunostained using anti-Myc (green) and anti-PML (red) antibodies (C). Cellular nuclei were stained by using DAPI (blue). Similar results were obtained in three
independent experiments and a representative experiment is shown. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
A. Brandariz-Nun˜ez et al. / Virology 435 (2013) 463–471 467discard the possibility that TRIM5arh is SUMOylated. We have
attempted to detect TRIM5arh SUMOylation by using a tagged
SUMO protein without any success, as tested by other groups
(Arriagada et al., 2011). The development of antibodies against
the endogenous TRIM5arh will allow the exploration of this
interesting possibility.
To directly test the ability of the PRYSPRY domain of TRIM5arh
to interact with SUMO protein, we tested the ability of recombi-
nant PRYSPRY domain from TRIM5arh to interact with SUMO-1 by
NMR spectroscopy. However, we were unable to detect any
interaction suggesting that TRIM5arh does not interact withSUMO-1. An alternative possibility is that the interaction with
SUMO-1 requires the full-length TRIM5arh, which is likely to
contain two PRYSPRY domains in close proximity, as previously
suggested (Arriagada et al., 2011).
We tested the role of SUMOylation in the restriction ability of
TRIM5ahu by using the SUMOylation inhibitor Gam1 (Boggio
et al., 2004, 2007; Colombo et al., 2002). For this purpose, we
used the human ﬁbrosarcoma cell line HT-1080 that expresses
TRIM5ahu and is able to potently block infection of N-MLV in a
TRIM5ahu-dependent manner. Even though Gam1 destroyed the
formation of PML nuclear bodies (Fig. 5C), it did not affect the
Fig. 6. Inhibition of SUMOylation by Gam1 does not affect the ability of TRIM5arh to trafﬁc into the nucleus. Human HT-1080 cells were cotransfected with plasmids
expressing Myc-tagged Gam1 and HA-tagged TRIM5arh. After 24 h, cells were treated with 20 ng/ml of leptomycin B (LMB) or DMSO for 5 h, ﬁxed and immunostained
using antibodies anit-myc (green) and anti-HA (red) antibodies. Cellular nuclei were stained by using DAPI (blue). Similar results were obtained in three independent
experiments(Supplementary Table 2), and a representative experiment is shown. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
Fig. 7. NMR titrations of the TRIM5arh PRYSPRY domain with SUMO-1. (A) The superposition of the 15N-HSQC spectra of the 0.3 mM 15N-labeled PRYSPRY sample in the
presence of 1.5 mM SUMO-1 (green) or in the absence of SUMO-1 added (red) is shown. Overlapping signals appear black. (B) NMR titrations of the 15N-labeled PRYSPRY
domain with SUMO-1 (blue) and the N-terminal domain of HIV-1 capsid (red). Addition of 5:1 M excess of SUMO-1 does not show any detectable attenuation of the
PRYSPRY NMR signals. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
A. Brandariz-Nun˜ez et al. / Virology 435 (2013) 463–471468ability of TRIM5ahu to restrict N-MLV suggesting that SUMOyla-
tion is not involved the ability of TRIM5ahu to restrict N-MLV.
Altogether these results suggested that the process of SUMOyla-
tion is not involved in the ability of TRIM5ahu to restrict N-MLV;
however, the use of Gam1 does not affect the levels of SUMO in
the cell, which could be important for restriction.
Interestingly, increasing the levels of SUMO-1 in human 293T
or TE671 cells increases the restriction imposed to N-MLV by
TRIM5ahu (Arriagada et al., 2011), arguing for a role of SUMO-1 in
restriction. One possibility is that the SUMOylation of capsid
described for Moloney murine leukemia virus is important
for the ability of TRIM5ahu to bind N-MLV capsid and restrict
infection (Yueh et al., 2006).
Taken altogether these ﬁndings do not support the role of SCM,
SIMs or SUMOylation in the ability of TRIM5a to restrict retroviralinfection. However, the contribution of the ability of TRIM5a to
shuttle into and out of the nucleus still remains unknown. The
future ﬁnding of TRIM5a variants that do not shuttle into and out
of the nucleus and bind the HIV-1 core will be essential to
uncover a role for nuclear shuttling on retroviral restriction by
TRIM5a.Materials and methods
Plasmid construction
The pLPCX-TRIM5a-HA plasmid, speciﬁc primers and a Quik-
Change site-directed mutagenesis kit (Stratagene) were used accord-
ing to the manufacturer’s speciﬁcations to generate recombinant
Fig. 8. Putative SUMO interaction motifs (SIM) mapped onto the TRIM5arh PRYSPRY structure. (A) SIM1, SIM2 and SIM3 mapped onto the TRIM5arh PRYSPRY
structure. The SPRY domain is shown as a cartoon with the protein surface colored in light green. The segments of the protein identiﬁed as SUMO interacting motifs SIM-1,
SIM-2 and SIM-3 are colored in cyan, orange and red respectively. Only the SIM-3 segment contains surface-exposed residues, while SIM-1 and SIM-2 are buried in the
hydrophobic core of the protein. (B) Slice through the TRIM5arh PRYSPRY structure showing the volume (green mesh) occupied by residues I376 and L377 of SIM1 (cyan).
The two residues are completely buried within the hydrophobic core and the lysine residues of the SIM1 mutant (magenta) cannot be accomodated within that space. The
resulting steric clash and buried positive charge are incompatible with the stably-folded native structure. (C) The same is true for SIM2. (D) In contrast, SIM3 is exposed on
the protein surface, therefore SIM3mut is not expected to disrupt the overall PRYSPRY structure. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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VI405KK and IV430KK. The plasmids expressing Gam1 and
Gam1-L258A/L265A proteins tagged with Myc epitope, was a
generous gift from Dr. Susanna Chiocca, and has been described
previously (Boggio et al., 2004).Antibodies
Monoclonal antibodies against the HA epitope were from
Sigma. Anti-GAPDH rabbit polyclonal antibodies, anti-mouse-
Cy2, anti-rabbit-Cy3, anti-mouse Alexa 488, and anti-goat Alexa
594 were obtained from Sigma. Anti-p24 HIV-1 capsid was
obtained from Immunodiagnostics. Anti-Myc monoclonal and
anti-PML goat polyclonal antibodies were purchased from Santa
Cruz Biotechnology.Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer, as previously described (Lienlaf et al.,
2011). Detection of proteins by Western blotting was performed
using anti-HA (Sigma), anti-GAPDH (Sigma), anti-P24 (Sigma),
anti-Myc (Santa Cruz Biotechnology) and anti-rabbit and anti-
mouse antibodies conjugated to Alexa Fluor 680 (Li-Cor). Bands
were detected by scanning blots with the Li-Cor Odyssey Imaging
System using the 700 channel.Binding of TRIM5arh variants to in vitro assembled HIV-1 capsid–
nucleocapsid (CA–NC) complexes
The HIV-1 CA–NC protein was expressed, puriﬁed, and
assembled as previously described (Lienlaf et al., 2011). HIV-1
CA–NC particles were assembled in vitro by diluting the CA–NC
protein to a concentration of 0.3 mM in 50 mM Tris–HCl (pH 8.0),
0.5 M NaCl and 2 mg/ml DNA oligo (TG)50. The mixture was
incubated at 4 1C overnight and centrifuged at 8600g for 5 min.
These CA–NC complexes were used for the binding assay as
follows: 293T cells were transfected with plasmids expressing
wild-type or mutant TRIM5arh proteins. Forty-eight hours after
transfection, cell lysates were prepared as follows: washed cells
were resuspended in hypotonic lysis buffer (10 mM Tris [pH 7.4],
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT). The cell suspension was
frozen and thawed and then incubated on ice for 10 min. Next,
the lysate was centrifuged at full speed in a refrigerated Eppen-
dorf microcentrifuge (14,000g) for 5 min. To test binding, 5 ml of
CA–NC complexes assembled in vitro were incubated with 200 ml
of cell lysate at room temperature for 1 h. A fraction of this
mixture was stored (input). The mixture was spun through a 70%
sucrose cushion (70% sucrose, 1 PBS, and 0.5 mM DTT) at
100,000g in an SW55 rotor (Beckman) for 1 h at 4 1C. After
centrifugation, the supernatant was carefully removed and the
pellet was resuspended in 1 SDS-PAGE loading buffer (pellet).
The level of TRIM5arh proteins was determined by Western
blotting using anti-HA antibodies (Sigma). The level of HIV-1
CA–NC protein in the pellet was assessed by Western blotting
with an anti-p24 capsid antibody (Immunodiagnostics).
A. Brandariz-Nun˜ez et al. / Virology 435 (2013) 463–471470Immunoﬂuorescence microscopy
Transfections of cell monolayers were performed using Lipo-
fectamine Plus reagent (Invitrogen), according to the manufac-
turer’s instructions. Transfected cells were incubated at 37 1C for
24 h, unless otherwise stated. For indirect immunoﬂuorescence
microscopy, cell monolayers grown on coverslips were trans-
fected. Monolayers were washed twice with PBS and ﬁxed for
15 min with 4% paraformaldehyde in PBS. Paraformaldehyde-
ﬁxed cells were washed twice with PBS, incubated for 4 min in
permeabilizing buffer (0.5% Triton X-100 in PBS), and then
blocked using PBS containing 2% bovine serum albumin for 1 h
at room temperature. Subsequently, cells were incubated for 1 h
at room temperature with primary antibodies in blocking buffer,
as previously described (Diaz-Griffero et al., 2002). After three
washes with PBS, the cells were incubated for 30 min with
secondary antibodies. Cellular nuclei were labeled with 1 mg/ml
of DAPI (49, 69-diamidino-2-phenylindole) in PBS. Subsequently,
samples were mounted for ﬂuorescence microscopy by using the
ProLong Antifade Kit (Molecular Probes, Eugene, OR). Images were
obtained with a Zeiss Observer.Z1 microscope using a 63
objective, and deconvolution was performed using the software
AxioVision V4.8.1.0 (Carl Zeiss Imaging Solutions).
Generation of cells stably expressing TRIM5arh variants
Retroviral vectors encoding wild-type or mutant TRIM5arh
were created using the pLPCX vector (Clontech). Recombinant
viruses were produced in 293T cells by cotransfecting the pLPCX
plasmids with the pVPack-GP and pVPack-VSV-G packaging
plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the
vesicular stomatitis virus G envelope glycoprotein, which allows
efﬁcient entry into a wide range of vertebrate cells (Yee et al.,
1994). Transduced Cf2Th cells were selected in 5 mg/ml of
puromycin.
Infection with viruses expressing green ﬂuorescent protein (GFP)
Recombinant HIV-1 expressing GFP was prepared as described
(Diaz-Griffero et al., 2008). The virus was pseudotyped with the
VSV-G glycoprotein. For infections, 5104 cells seeded in 24-well
plates were incubated at 37 1C with virus for 24 h. Cells were
washed and returned to culture for 48 h unless otherwise stated,
and the percentage of GFP positive cells was determined by ﬂow
cytometry (Becton Dickinson). Viral stocks were titrated by serial
dilution on Cf2Th cells to determine the concentration of infec-
tious viruses.
Cross-linking of TRIM5arh
The HA-tagged TRIM5arh variants were expressed transiently
in 293T cells. Cells were washed in phosphate-buffered saline
(PBS) and lysed in NP40 lysis buffer (0.5% Nonidet P40 (NP40),
1 protease inhibitor (complete EDTA-free, Roche Diagnostics) in
PBS) for 45 min at 4 1C. Lysates were centrifuged at 14,000g for
15 min at 4 1C. The cleared lysates were not stored or frozen, but
rather were directly cross-linked. Approximately 100–200 ml of
cleared lysates was diluted with PBS/1 mM EDTA to a ﬁnal
volume of 400 ml. Lysates were cross-linked with varying con-
centrations (up to 2 mM) of ethylene glycol-bis(succinimidyl
succinate) (EGS) for 30 min at room temperature and centrifuged
brieﬂy in a tabletop centrifuge. The reaction mix was quenched
with 0.1 M Tris–HCl, pH 7.5 and brieﬂy centrifuged. The cleared,
cross-linked lysates were analyzed by Western blotting using
antibodies against HA epitope (Sigma).Recombinant proteins preparation
The pET28b expression vector encoding the SUMO1 with a
C-terminal 6His tag was a generous gift from Dr. Christopher
Lima. Transformed BL21 Rosetta 2 competent cells (Novagen)
were grown at 37 1C until cell density reached A600–0.6. The
temperature was then lowered to 30 1C and protein production
was induced with 0.75 mM isopropyl-b-D-thiogalactopyranoside
(IPTG). After 4 h cells were harvested by centrifugation (6000g)
and lysed by sonication. The puriﬁcation of the C-terminally
His-tagged SUMO-1 was carried out by metal afﬁnity followed
by size-exclusion chromatography on a Superdex 75 (GE life
sciences). The cloning, expression and puriﬁcation of PRYSPRY
domain from TRIM5arh have been described previously (Biris
et al., 2012). All NMR samples were prepared in 50 mM sodium
phosphate pH 7.0, 50 mM NaCl and 10 mM dithiothreitol buffer.
NMR titrations
NMR titrations of 15N-labeled PRYSPRY domain of TRIM5arh
with unlabeled His-tagged SUMO1 and unlabeled N-terminal
domain of the HIV capsid (residues 1–147) were carried out on
a Bruker Avance 700 MHz spectrometer at 298 K by recording a
series of 1H–15N TROSY-HSQC spectra containing molar ratios
from 1:0 up to 1:5 for SUMO1 and from 1:0 up to 1:7 for the
N-terminal domain of HIV-1 capsid.Acknowledgments
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